Clinical Trials
Below are current clinical trials.
269 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla.
The purpose of this study is to prospectively collect longitudinal stool specimens and corresponding clinical and patient provided data from asymptomatic patients or those with history of exposure or patients presenting with symptoms suggestive of COVID-19 who are undergoing testing for the novel SARS-CoV-2 virus to enable high quality research.
-
Jacksonville, Fla.
The purpose of this study is to assess levels of caffeine intake among patients who tested positive for COVID-19 infection and compare that to disease severity.
-
Jacksonville, Fla., Rochester, Minn.
The purpose of this study is to evaluate the effectiveness of ALIS + azithromycin (AZI) + ethambutol (ETH) compared to the empty liposome control (ELC) + AZI + ETH on patient reported respiratory symptoms at Month 13.
-
Scottsdale/Phoenix, Ariz.
This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the primary symptom of recurrent Clostridium difficile infection. All eligible subjects will receive RBX2660.
-
Rochester, Minn.
The purposes of this study are to prevent COVID-19 (CoV) disease complications by a 7 point score adapted from the World Health Organization (WHO) Ordinal Scale for Clinical Improvement of CoV, to evaluate safety and tolerability of Fisetin in this patient population, to reduce progression of severity of CoV infections with no, mild, or moderate to severe or critical symptoms (WHO/National Institutes of Health (NIH) Baseline Categorization), and to decrease senescent cells, inflammation, and physical dysfunction (frailty).
-
Rochester, Minn.
The purpose of this study is to compare the efficacy and safety of maribavir to valganciclovir for the treatment of cytomegalovirus (CMV) infection in asymptomatic hematopoietic stem cell transplant recipients.
-
Rochester, Minn.
The purpose of this study is to compare the efficacy of brincidofovir (BCV) to valganciclovir (vGCV) for the prevention of CMV disease in kidney transplant recipients who are CMV seropositive pretransplant and received antilymphocyte induction therapy.
-
Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate the safety and efficacy of ABT-493 and ABT-530 (or ABT-493/ABT-530) coadministered with and without ribavirin in adults with chronic HCV genotypes 2, 3, 4, 5 or 6 infection. In part 4, the primary objectives also include to assess the efficacy (SVR12) of treatment with ABT-493/ABT-530 combination regimen in GT2-infected DAA-naive subjects without cirrhosis compared to historical SVR12 rate of treatment with sofosbuvir plus RBV in GT2-infected DAA-naive subjects without cirrhosis.
-
Rochester, Minn.
The purpose of this study is to determine the safety and tolerability of ixazomib in HIV infected patients who are on a stable regimen of ART that suppresses HIV replication, and to determine the effectiveness of ixazomib on reservoir T cells that are infected with HIV DNA.
-
Rochester, Minn.
Subjects who had a CDI recurrence in Study SERES-012 within 8 weeks of receipt of study drug will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days. The purpose of this study is to assess safety and efficacy of SER-109 in reducing recurrence of Clostridium difficile infection (CDI) in adults who had a CDI recurrence within 8 weeks after receipt of SER-109 or Placebo in Study SERES-012.